{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:46:04Z","timestamp":1774075564431,"version":"3.50.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.2169\/internalmedicine.5970-25","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T22:07:21Z","timestamp":1756332441000},"page":"852-856","source":"Crossref","is-referenced-by-count":0,"title":["Fulminant Type 1 Diabetes Induced by Immune Checkpoint Inhibitors in a Patient with Autoimmune Predisposition"],"prefix":"10.2169","volume":"65","author":[{"given":"Miyu","family":"Tomiki","sequence":"first","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Matoba","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Jinnai","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital East, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimei","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ascierto PA, Palmieri G, Gogas H. What is changing in the adjuvant treatment of melanoma? Oncotarget 8: 110735-110736, 2017.","DOI":"10.18632\/oncotarget.22988"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Baden MY, Imagawa A, Abiru N, et al.; the consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10: 58-66, 2019.","DOI":"10.1007\/s13340-018-0362-2"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kawabata Y, Ikegami H, Awata T, et al.; the Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 52: 2513-2521, 2009.","DOI":"10.1007\/s00125-009-1539-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ono M, Nagao M, Takeuchi H, et al. HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis. Eur J Endocrinol 191: 9-16, 2024.","DOI":"10.1093\/ejendo\/lvae081"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67: 1471-1480, 2018.","DOI":"10.2337\/dbi18-0002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. de Filette JMK, Pen JJ, Decoster L, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol 181: 363-374, 2019.","DOI":"10.1530\/EJE-19-0291"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care 7: e000591, 2019.","DOI":"10.1136\/bmjdrc-2018-000591"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Yun K, Daniels G, Gold K, McCowen K, Patel SP. Rapid onset type 1 diabetes with anti-PD-1 directed therapy. Oncotarget 11: 2740-2746, 2020.","DOI":"10.18632\/oncotarget.27665"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tsang VHM, McGrath RT, Clifton-Bligh RJ, et al. Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes. J Clin Endocrinol Metab 104: 5499-5506, 2019.","DOI":"10.1210\/jc.2019-00423"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Qiu J, Luo S, Yin W, et al. Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin. Front Immunol 13: 968798, 2022.","DOI":"10.3389\/fimmu.2022.968798"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T. Case report: strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes. Front Endocrinol (Lausanne) 15: 1407192, 2024.","DOI":"10.3389\/fendo.2024.1407192"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Liu YC, Liu H, Zhao SL, Chen K, Jin P. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China. Front Immunol 14: 1164120, 2023.","DOI":"10.3389\/fimmu.2023.1164120"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Hara N, Suwanai H, Yakou F, et al. Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study. Endocrine 81: 477-483, 2023.","DOI":"10.1007\/s12020-023-03394-8"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Wu L, Tsang V, Menzies AM, et al. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care 46: 1292-1299, 2023.","DOI":"10.2337\/dc22-2202"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lee S, Morgan A, Shah S, Ebeling PR. Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy. Endocrinol Diabetes Metab Case Rep 2018: 18-0021, 2018.","DOI":"10.1530\/EDM-18-0021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Usui Y, Udagawa H, Matsumoto S, et al. Association of serum anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by nivolumab in patients with non-small cell lung cancer. J Thorac Oncol 12: e41-e43, 2017.","DOI":"10.1016\/j.jtho.2016.12.015"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gauci ML, Laly P, Vidal-Trecan T, et al. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother 66: 1399-1410, 2017.","DOI":"10.1007\/s00262-017-2033-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lowe JR, Perry DJ, Salama AK, Mathews CE, Moss LG, Hanks BA. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer 4: 89, 2016.","DOI":"10.1186\/s40425-016-0196-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4: 173-182, 2018.","DOI":"10.1001\/jamaoncol.2017.3064"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5970-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:34:01Z","timestamp":1774064041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5970-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5970-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"article-number":"5970-25"}}